CTRI/2015/12/006462已完成2 期
A Two Arm, Randomized, Multicenter, Single blind, Prospective, Clinical study to evaluate efficacy & safety of PS/MAR/HO-1 oil and a marketed formulation in mild to moderate Hair loss in females - NI
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Marico Ltd
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Female subjects between the age group of 18- 40 years both inclusive
- •2.Subjects suffering from mild to moderate hair loss (by comb test).
- •3.Subjects who are infrequent hair oil users
- •4.Subjects who are willing to give informed consent and ready to comply with the protocol
- •5.Subjects who are ready to provide regular follow ups till the completion of the study
排除标准
- •1.Subjects with severe Hair fall due to any clinically significant disorders.
- •2.Subject with severe dermatological disorders of the scalp
- •3.Subjects with recent disease history like, malaria, typhoid, jaundice & scalp diseases
- •4.Subjects who have regularly used anti-hair fall treatment with hair oils over last 6 months.
- •5.Subjects who have previously undergone hair transplantation
- •6.Subjects on immunosuppressive drugs
- •7.Subjects on systemic steroids for more than 14 days within last 2 months
- •8.Pregnant/planning a pregnancy or lactating, menopausal Women
研究者
相似试验
已完成
不适用
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV MelanomaPER-056-07BRISTOL MYERS SQUIBB PERU S.A.,
进行中（未招募）
不适用
A Multi-Center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients withUntreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine With Placebo.Revised Protocol 04, incorporating Administrative Letter 01, Administrative Letter 02, Administrative Letter 03, Amendment 02, Amendment 06 and Amendment 07.Stage III (Unresectable) or IV MelanomaEUCTR2005-006082-14-ATBristol-Myers Squibb International Corporation500
进行中（未招募）
不适用
A Multi-Center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients withUntreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine With Placebo.Revised Protocol 03, incorporating Administrative Letter 01, Administrative Letter 02, Amendment 02, and Amendment 06EUCTR2005-006082-14-HUBristol-Myers Squibb International Corporation500
进行中（未招募）
不适用
A Multi-Center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients withUntreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine With Placebo.Revised Protocol 03, incorporating Administrative Letter 01, Administrative Letter 02, Amendment 02, and Amendment 06Stage III (Unresectable) or IV MelanomaEUCTR2005-006082-14-PTBristol-Myers Squibb International Corporation500
已完成
3 期
A Multi-Center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients with Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine With Placebomelanosarcomaskincancer10040900NL-OMON34151Bristol-Myers Squibb12